Navigation Links
PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
Date:6/26/2012

MANSFIELD, Mass., June 26, 2012 /PRNewswire/ -- PrimeraDx, a molecular diagnostics company, today announced that it has entered into a multi-year relationship with Eli Lilly and Company to develop diagnostic products in support of multiple clinical development programs for novel therapeutics.  Under the terms of this agreement, the two companies will collaborate to develop innovative multiplex assays on PrimeraDx's clinical platform, the ICEPlex® System.

Dr. Matt McManus, President and CEO of PrimeraDx said, "This relationship really moves our company forward in achieving our goals of bringing personalized medicine to the clinic and being the leader in the high-value companion diagnostics space. These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients.  We are very excited about collaborating with Lilly on these important programs."

"We have great expectations of our collaboration with PrimeraDx," said Dr. Andrew Schade, Senior Director, Clinical Diagnostics Laboratory at Lilly.  "The unique ability of the ICEPlex System to combine multiple DNA and RNA biomarkers into a single multiplex assay could prove invaluable in our drive to develop companion diagnostics for crucial assets in our clinical pipeline.

"Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas," added Schade.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed and is commercializing a novel, game-changing clinical platform which combines PCR with capillary electrophoresis. The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed, multi-modal and quantitative answers to the clinic. A key advantage of this next-generation quantitative PCR technology is the ability to rapidly configure very complex multi-modal assays that test for disparate target types, such as SNPs, expression biomarkers, microRNAs and fusion genes.

The Company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.

The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysian Technology Development Corporation.

The Company's website is: www.primeradx.com or www.multiplexpcr.com.  CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Research and Markets has announced the addition of the ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be ... & Exposition, the event will take place February 23-25, 2017 at the Calvin L. ... in Booth #909 with three new ambulances on display. , “JEMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory from ... points to easily connect elderly veterans of America's armed forces to a range ... also conveys material on this year's increase in the Veterans Pension with Aid ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):